A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients

You may not qualify if:

• Patients in the acute infection stage;
• Confirmed AIDS patients；
• Patients who have received antiviral therapy and/or have been vaccinated against HIV；
• HBsAg is (+), and/or anti-HCV is (+)；
• Abnormal liver function tests (ALT and / or AST\> 3ULN, or total bilirubin\> 2ULN)；
• Glomerular filtration rate \<70mL/min/1.73m2, or creatinine ≥ULN；
• Patients who is currently suffering from a more serious chronic diseases, metabolic diseases (such as diabetes), neurological and mental diseases；
• Patients who have previous history of pancreatitis；
• Females who are pregnant or breastfeeding, or females of childbearing age who are unable to take contraception as required;
• Allergic constitution or known allergy to the components of study drug；
• With a history of smoking addiction within 12 months before screening (average number≥5 cigarettes per day)；
• With a history of alcohol abuse within 12 months before screening (average drinking≥14 units of alcohol per week: 1 unit = 285mL beer, 25mL spirits, or 150mL wine) or those who have a positive alcohol breath test before enrollment；
• With a history of drug abuse within 12 months before screening or those who tested positive for addictive substances before enrollment；
• Patients who have participated in other investigational drug study within 3 months before screening (except for traditional Chinese medicine）；
• Other factors that the investigators consider unsuitable for the trial.